A CROSS-SECTIONAL OBSERVATIONAL STUDY TO ANALYSE PRESCRIPTION PATTERN OF PROTON PUMP INHIBITORS IN A TERTIARY CARE TEACHING HOSPITAL
Abstract
The approved indications of proton pump inhibitors (PPIs) do not include generalized acid suppression. Rather these agents should be used for various forms of gastroesophageal reflux disease (GERD), patients receiving non-steroidal anti-inflammatory drugs (NSAIDs) with high bleeding risk. Several reports are available which show that chronic inappropriate use of PPIs results in severe adverse effects. Recent systemic reviews and meta-analyses studying the prescription pattern of PPIs in India over the last two decades revealed that the PPIs are being overprescribed, and prescribed for indications other than the approved indications. With this background, the current study was planned to explore the prescription and usage pattern of PPIs in a tertiary care teaching hospital. The present study was a cross-sectional observational study conducted at the punjab institute of medical sciences, Jalandhar after obtaining Institutional Ethics Committee (IEC) approval. The prescriptions received at the pharmacy department of the hospital from different open publication distribution system (OPDs) were screened.The data regarding demographics of the patient (gender, age), the prescribing department, and the total number of drugs prescribed per prescription was collected. Further, the prescriptions were analysed according to World Health Organization (WHO) prescribing indicators. It was observed that every second prescription received in the pharmacy department was of PPIs. In total 1000 prescriptions were screened and 500 prescriptions were for PPIs. 63% of the prescriptions were from female patients and the rest of the prescriptions were from male patients. The majority of the patients (58.4%) were in the age group of 18 to 40 years. 95.2% of the prescriptions contained PPIs in fixed-dose combination (FDCs) formulation. The most frequently prescribed PPI as a mono drug was pantoprazole (2.4%).The second active pharmaceutical ingredient (API), in all the FDCs, was observed to be a prokinetic agent, either domperidone or itopride. Only 4.8% of the prescriptions were from the gastroenterology clinic. The analysis of the prescription using WHO prescribing criteria showed that the average number of drugs prescribed per encounter was 4.63 and only 0.4% of the drugs were prescribed from National List of Essential Medicines (NLEM). The drugs prescribed by generic name were 81.4% against the optimal level of 100%. It can be concluded that PPIs are being prescribed without appropriate indication in most cases. These findings suggest the need for sensitization programs for practitioners for prescribing practices and appropriate use of PPIs.
Keywords:
Drug Utilization, Prescribing Indicators, GERD, Antisecretory Drugs, Essential MedicinesDOI
https://doi.org/10.25004/IJPSDR.2022.140509References
World Health Organization. Introduction to drug utilization research. 2003 https://apps.who.int/iris/bitstream/handle/10665/42627/924156234X.pdf?sequence=1&isAllowed=y.
Goyal AM, Gor AP. Prescribing Pattern of Proton Pump Inhibitors (PPI) and Histamine Blockers in a Tertiary Care Hospital. J Clin Diagn Res. 2020; 14(10): FC01-FC03.
George CJ, Korc B, Ross JS. Appropriate proton pump inhibitor use among older adults: a retrospective chart review. Am J. Geriatr Pharmacother. 2008;6(5):249–254.
Sukhovershin RA, Cooke JP. How may proton pump inhibitors impair cardiovascular health?Am J Cardiovasc Drugs. 2016;16(3):153–161.
Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008:336 (7634);2-3.
Gamelas V, Salvado V, Dias L. Prescription Pattern of Proton Pump Inhibitors at Hospital Admission and Discharge. GE Port J Gastroenterol. 2019:26;114–120.
Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting 2002-2009. PLOS ONE. 2013:8(2); e56060.
Souza AM, Shastry CS, Mateti UV, Kabekkodu S, Chand S. Drug utilization and evaluation of proton pump inhibitors in general medicine ward of a tertiary care hospital. J. Pharm Sci Res. 2019: 11(6);2174-2179.
Lenoir C, Biali ME, Luthy C, Grosgurin O, Desmeules JA, Rollasonm V. Snapshot of proton pump inhibitors prescriptions in a tertiary care hospital in Switzerland: less is more? Int J. Clin Pharm. 2019:41(6);1634-1641.
Laheij RJF, Sturkenboom MCJM, Hassing RJ, Dieleman J, Stricker BHC,Jansen JBMJ.Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004: 292(16);1955-1960.
Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018: 67(1);28–35.
Torpey N, Barker T, Ross C. Drug-induced tubulointerstitial nephritis secondary to proton pump inhibitors: experience from a single UK renal unit. Nephrol Dial Transplant.2004:19 (6);1441-1446.
Härmark L, van der Wiel HE, de Groot MCH, van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. Br J. Clin Pharmacol. 2007:64(6); 819-823.
Koop H, Bachem MG. Iron Serum and ferritin vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992:14 (4);288–292.
Airee RS, Rawal A, John NN, Binu KM. Drug use evaluation of proton pump inhibitors in a private tertiary care teaching hospital. J. Adm Pharm. 2016:5(1);922-930.
Liu Y, Zhu X, Li R, Zhang J, Zhang F. Proton pump inhibitor utilisation and potentially inappropriate prescribing analysis: insights from a single-centred retrospective study. BMJ Open. 2020;10 (11): e040473.
Luo H, Fan Q, Xiao S, Chen K. Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists’ effect on prescribing practice at a tertiary hospital. BMC Health Serv Res. 2018: 18(1); 537.
Venkataraman R, Rashid M, Shrestha H. Inappropriate Medication Use and Cost Comparison Analysis of Proton Pump Inhibitors: Evidence from an Indian Tertiary Care Facility. Curr Drug Saf. 2020:15(2);147-155.
National List of Essential Medicine (NLEM) (2015) https://main.mohfw.gov.in/sites/default/files/NLEM%2C%202015.pdf (Accessed December 20 2022).
World Health Organization, “Model Lists of Essential Medicines”, https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-list s. (Accessed December 15 2022).
Drug Controller General of India Approved fixed-dose combination, (2019-21)
https://cdsco.gov.in/opencms/opencms/en/Approval_new/FDC-New-Drugs-Marketing/ (Accessed December 18 2022)
Ofori-Asenso Richard. A closer look at the World Health Organization’s prescribing indicators. J Pharmacol Pharmacother. 2016:7(1);51–54.
Ahad MZ, Alekhya L, Maria A, Raviraj A,RajeshV. A Cross- Sectional Study on Single-Day Use of Proton Pump Inhibitors in Ter tiar y Care Hospitals of South India. J. Hosp Pharm. 2021:56(2);109-111.
Farrell B, Pottie K, Thompson W. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline, Can Fam Physician. 2017:63(5);354-364.
Biswas M, Kritarth NMS, Mithileshwar S, Shetty YC, Koli PG, Sushrut I, Bhatia SJ. Prescription pattern & adverse drug reactions of prokinetics. Indian J. Med Res. 2019:149(6);48–754.
Marakhouski KY, Karaseva GA, Ulasivich DN, Marakhouski YK. Omeprazole-Domperidone Fixed-Dose Combination vs Omeprazole Monotherapy: A Phase 4, Open-Label, Comparative, Parallel Randomized Controlled Study in Mild to Moderate Gastroesophageal Reflux Disease. Clin Med Insights Gastroenterol. 2017:10; 1179552217709456.
Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S, Ashida K, Ohara S, Kashiwagi H, Adachi K, Higuchi K, Miwa H, Fujimoto K, Kusano M, Hoshihara Y, Kawano T, Haruma K, Hongo M, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for gastroesophageal reflux disease. J. Gastroenterol. 2016:1(8); 751-767.
Scarpignato C, Hongo M, Wu JCY, Lottrup C, Lazarescu A, Stein E, Richard HRH. Pharmacologic treatment of GERD: Where we are now, and where are we going? Ann N Y Acad Sci. 2020:1482(1);193-212.
Dharmarajan TS.The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing. J. Ame Med Director Asscoc. 2021:22 (1);15-22.
Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E. Proton pump inhibitors: use and misuse in the clinical setting. Expert Rev Clin Pharmacol. 2018:11(11);1123-1134.
Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010:16 (2);122-129.
Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016:14 (1);179.
Bhagavathula A S , Vidyasagar K , Chhabra M, Rashid M, Sharma R, Bandari DK, Fialova D. Prevalence of Polypharmacy, Hyperpolypharmacy and Potentially Inappropriate Medication Use in Older Adults in India: A Systematic Review and Meta-Analysis. J. Front Pharmacol. 2021:12;685518.
Published
Abstract Display: 461 
PDF Downloads: 379 
